AbbVie (NYSE: ABBV), in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced the completion of a Phase 2b clinical...
Read moreCompany Initiates Pivotal Phase 3 Studies Evaluating Relebactam in Combination with Imipenem/Cilastatin for Treatment of Serious Bacterial Infections known as...
Read moreBristol-Myers Squibb Company announced results from a 7-year, long-term follow-up from a prospective, randomized Phase III trial (BENEFIT) in kidney...
Read moreToday announced that primary endpoints were successfully met in ALLY-1, a Phase III clinical trial evaluating a 12-week regimen of...
Read moreAlizé Pharma, a company specialized in the development of drugs for the treatment of metabolic disorders and rare diseases, today...
Read moreTeva Pharma announced positive new data from Phase III studies of the company’s anti-IL5 monoclonal antibody, reslizumab, in patients with...
Read moreCore Phase III clinical trial program complete; BIL showed consistent HbA1c superiority against comparators Lilly expects U.S. and European regulatory...
Read more'No evidence of disease activity' (NEDA), the ultimate treatment goal in MS, is currently assessed by measuring relapses, MRI lesions...
Read more- FREESTYLE LIBRE SYSTEM ELIMINATES ROUTINE FINGER PRICKS FOR GLUCOSE MEASUREMENTS1 AND REQUIRES NO FINGER PRICKS FOR CALIBRATION - AVAILABLE...
Read moreFirst presentation of LANTERN study to confirm superior efficacy of once-daily Ultibro® Breezhaler® versus Seretide® Accuhaler®* in COPD patients QUANTIFY...
Read more
Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.
